Health Care • Biotechnology: Pharmaceutical Preparations
$11.15 ▼ -0.40
(-3.46%)
MKT CAP: $324.7M • VOL: 218.5K
52W L $10 52W H $17
ENTA // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-09-30 | FY 2024
FILED 2024-09-30 | FY 2023
FILED 2023-09-30 |
|---|---|---|---|
| Revenue (Total Sales) | $65.3M | $67.6M | $79.2M |
| YoY Revenue Growth % | -3.4% | -14.6% | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$85.3M | -$121.7M | -$137.2M |
| Operating Margin % | -80.0% | -80.0% | -80.0% |
| Net Income (GAAP) | -$81.9M | -$116.0M | -$133.8M |
| EBITDA (Normalized) | -$75.0M | -$107.3M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$19.3M | -$78.8M | -$103.2M |
| Capital Expenditures (CapEx) | $12.9M | $17.9M | — |
| Free Cash Flow (FCF) | -$32.2M | -$96.7M | -$103.2M |
| FCF Margin % | -49.2% | -80.0% | -80.0% |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $37.4M | $84.3M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $126.6M | $111.8M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR ENTA.